X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FOTIVDA (tivozanib) is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, which is investigated in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma.
Lead Product(s): Tivozanib,Nivolumab
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
AVEO will establish LG Chem’s commercial presence in oncology through AVEO’s lead product, FOTIVDA® (tivozanib), which received U.S. FDA approval for the treatment of relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.
Lead Product(s): Tivozanib
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: LG Chem
Deal Size: $566.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 18, 2022
Details:
FOTIVDA® (tivozanib) is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.
Lead Product(s): Tivozanib
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Under the terms of the agreement, Lilly will provide cetuximab clinical drug supply in the U.S. and Canada for AVEO’s potential registrational study, which will assess AV-299 (ficlatuzumab) with cetuximab in HPV negative R/M HNSCC.
Lead Product(s): Ficlatuzumab,Cetuximab
Therapeutic Area: Oncology Product Name: AV-299
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Eli Lilly
Deal Size: $3.7 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 22, 2022
Details:
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of Fotivda (tivozanib), patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib.
Lead Product(s): Tivozanib,Nivolumab
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Actinium to apply its proprietary Antibody Warhead Enabling (AWE) technology platform to perform conjugation of AVEO's ErbB3 targeted antibody with Actinium-225, a potent alpha-emitting radioisotope, to form a novel Ac-225 ErbB3 targeted radiotherapy.
Lead Product(s): Actinium-225 Conjugated Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Actinium pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2022
Details:
Five year follow-up data show FOTIVDA® (tivozanib), next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor patients up to 5X more likely to experience long-term PFS compared to Nexavar.
Lead Product(s): Tivozanib
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
First-line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of Fotivda (tivozanib) plus Imfinzi (durvalumab) in first-line HCC.
Lead Product(s): Tivozanib,Durvalumab
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
The collaboration with NiKang, will play an important role in the advancement of both tivozanib and NKT2152 program. Under the terms of the agreement, NiKang will sponsor the trial and AVEO will co-fund the trial. Both companies will provide its respective drugs at no cost.
Lead Product(s): NKT2152,Tivozanib
Therapeutic Area: Oncology Product Name: NKT2152
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: NiKang Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2022
Details:
The net proceeds of the offering are used to support commercialization activities relating to Fotivda (tivozanib) and to advance AVEO’s pipeline. Fotivda is the first and only approved treatment specifically for advanced kidney cancer or renal cell carcinoma.
Lead Product(s): Tivozanib
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Leerink
Deal Size: $55.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
